Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving blood stem cell transplantation. What we do: • For healthy immune systems, our immunotherapy programs temporarily boost the immune system so that it functions better to fight both solid tumors and infectious disease. • For compromised immune systems, our regenerative medicine program generates a new, healthy immune system. 1. Our lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells to help fight against solid tumors and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. Our Cell-Based Immunotherapy technology has several advantages over current immunotherapy approaches. • We do not need to expand T-cells in the laboratory to generate enough T-cells for treatment. • We do not limit the response to the tumor based by engineering the specificity of the T-cell. • We do not require genetic modification of the T-cells to enable antitumor activity. 2. Our Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-2400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Our BMEE goal is to increase the chance of long-term survival of a HSCT recipient by: • increasing the probability of a successful engraftment; • increasing the rate of reconstitution of mature and functional lymphocytes; and • managing the complications associated with HSCT.